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Inhaled corticosteroids in COPD and onset of type 2 diabetes
and osteoporosis: matched cohort study
David B. Price 1,2*, Jaco Voorham1, Guy Brusselle3, Andreas Clemens 4,5, Konstantinos Kostikas 4,10, Jeffrey W. Stephens 6,
Hye Yun Park7, Nicolas Roche8 and Robert Fogel 9
Some studies suggest an association between onset and/or poor control of type 2 diabetes mellitus and inhaled corticosteroid (ICS)
therapy for chronic obstructive pulmonary disease (COPD), and also between increased fracture risk and ICS therapy; however,
study results are contradictory and these associations remain tentative and incompletely characterized. This matched cohort study
used two large UK databases (1983–2016) to study patients (≥ 40 years old) initiating ICS or long-acting bronchodilator (LABD) for
COPD from 1990–2015 in three study cohorts designed to assess the relation between ICS treatment and (1) diabetes onset
(N= 17,970), (2) diabetes progression (N= 804), and (3) osteoporosis onset (N= 19,898). Patients had ≥ 1-year baseline and
≥ 2-year outcome data. Matching was via combined direct matching and propensity scores. Conditional proportional hazards
regression, adjusting for residual confounding after matching, was used to compare ICS vs. LABD and to model ICS exposures.
Median follow-up was 3.7–5.6 years/treatment group. For patients prescribed ICS, compared with LABD, the risk of diabetes onset
was signiﬁcantly increased (adjusted hazard ratio 1.27; 95% CI, 1.07–1.50), with overall no increase in risk of diabetes progression
(adjusted hazard ratio 1.04; 0.87–1.25) or osteoporosis onset (adjusted hazard ratio 1.13; 0.93–1.39). However, the risks of diabetes
onset, diabetes progression, and osteoporosis onset were all signiﬁcantly increased, with evident dose–response relationships for
all three outcomes, at mean ICS exposures of 500 µg/day or greater (vs. < 250 µg/day, ﬂuticasone propionate–equivalent). Long-
term ICS therapy for COPD at mean daily exposure of ≥ 500 µg is associated with an increased risk of diabetes, diabetes progression,
and osteoporosis.
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INTRODUCTION
The identiﬁcation of patients who are most likely to beneﬁt from
inhaled corticosteroids (ICS) for chronic obstructive pulmonary
disease (COPD) remains an important topic of research and of
interest for the clinical community.1–3 In addition, the adverse
effects of ICS therapy for COPD—the risk side of the risk-beneﬁt
equation—remain incompletely characterized and require further
investigation.4
Well-accepted adverse effects associated with ICS therapy in
COPD include increased risk of pneumonia, as well as skin
bruising, oropharyngeal candidiasis, hoarse voice, and increased
risk of tuberculosis.4–6 Other potential adverse effects of ICS are
less well-characterized and considered not deﬁnitive in the current
Global Initiative for Chronic Obstructive Lung Disease (GOLD)
strategy publication, such as the risks of diabetes, poor control of
diabetes, decreased bone density, and fracture.4 Although some
cohort studies report increased risk of onset and progression of
diabetes, particularly at higher ICS doses,7,8 other cohort studies
and reviews of controlled trial results ﬁnd no such association.9,10
Similarly, discordant results have been published for the associa-
tion of ICS with risk of fracture,6,11 although a recently published
large case–control study of patients with COPD followed until
March 2007 found that long-term, high-dose ICS was associated
with a modest increase in the risk of hip and upper extremity
fractures.12
Many prior studies of ICS adverse effects for patients with COPD
suffer from important limitations. In particular, most randomized
controlled trials are not sufﬁciently powered or long enough to
evaluate adverse effects. Moreover, many observational studies
have been criticized for patient selection and time-related biases,3
and patients with concomitant asthma may not be speciﬁcally
excluded.3,7,8
The current GOLD strategy recommends limiting ICS-containing
therapy to patients in GOLD group D who experience frequent
COPD exacerbations and persistent symptoms despite optimal
bronchodilator therapy with long-acting bronchodilators (LABD)
and who have a blood eosinophil count ≥ 300 cells/µL.4,13
However, discrepancies have frequently been reported between
GOLD recommendations and clinical practice, where ICS are
widely prescribed for COPD, typically in combination with long-
acting β-agonist (LABA) or as monotherapy,14–16 with up to 60% of
patients in GOLD groups A and B initiated on ICS-containing
therapy in some studies.16,17 This is particularly concerning given
that patients with COPD are typically older, thus more likely to
have pre-existing comorbidities.2,3,5
The aim of this large, historical matched cohort study was to
evaluate whether ICS therapy for patients with COPD is associated
with an increased onset or accelerated progression of type 2
diabetes mellitus, or with an increased onset of osteoporosis. We
were able to access large medical record databases to evaluate
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median ICS exposure durations of over 5 years. Our primary
objective was to compare the association of onset and progres-
sion of diabetes, and onset of osteoporosis, between patients
prescribed ICS (with or without LABDs) compared with LABDs and
to examine these outcomes according to different levels of mean
daily and cumulative ICS exposure, both for all matched patients
and stratiﬁed by GOLD groups assigned using the GOLD
2011 strategy.18
RESULTS
Patients
We identiﬁed 152,516 patients in the Clinical Practice Research
Datalink (CPRD) and Optimum Patient Care Research Database
with a recorded COPD diagnosis preceding maintenance treat-
ment initiation for COPD from 1990 to August 2015, including
104,519 and 47,997 patients initiating ICS and LABD therapy,
respectively. Of these, 28,060 (27%) and 9862 (21%) patients,
respectively, were eligible for the study after we applied general
eligibility criteria and eliminated duplicate patients (see online
Supplementary Fig. 1).
Of the total of 37,922 eligible patients, 33,934 (89%), 1346
(3.5%), and 36,154 (95%) were eligible for the diabetes onset,
diabetes progression, and osteoporosis onset cohorts, respec-
tively. After matching, the two treatment groups totaled 17,970
patients in the diabetes onset cohort, 804 patients in the diabetes
progression cohort, and 19,898 patients in the osteoporosis onset
cohort, representing 53%, 60%, and 55% of the unmatched
cohorts, respectively. Baseline demographic and clinical charac-
teristics of the unmatched treatment groups of each study cohort
are in the online Supplementary Tables 1–3, and baseline
characteristics of the matched treatment groups are summarized
in Tables 1–3, with additional baseline characteristics reported in
Supplementary Tables 4–6.
The mean ages of the matched treatment groups were 68, 71,
and 68 years in diabetes onset, diabetes progression, and
osteoporosis onset cohorts, respectively. Patients in the diabetes
progression cohort included a slightly higher percentage of men
(59%, 66%, and 62%, respectively). Approximately half of patients
in each study cohort had experienced one or more moderate-to-
severe exacerbations in the baseline year, and in each ICS
treatment group in the three study cohorts, 60% or 61% of
patients in the 2011 GOLD A/B groups were prescribed ICS (see
Tables 1–3).
Length of baseline period and follow-up
The median baseline period before the ﬁrst prescription of ICS or
LABD ranged from 15.6 to 17.5 years in the two matched
treatment groups of each study cohort, whereas median outcome
periods after the index date ranged from 3.7 to 5.6 years, with the
longer outcome periods in ICS treatment groups (Table 4).
Outcome event rates
Patients initiating ICS had a mean rate of diabetes onset of 1.25 vs.
1.05 diagnoses per 100 patient-years for the LABD initiators
(online Supplementary Table 7). The mean rates of diabetes
progression were 33.3 vs. 37.2 per 100 patient-years for ICS vs.
LABD initiators. In the osteoporosis onset cohort, the rate of
osteoporosis diagnosis was 0.70 vs. 0.66 diagnoses per 100
patient-years, respectively.
ICS vs. LABD initiation: all patients and by GOLD group
Results of the Cox proportional hazards models indicated that
patients in the ICS group were more likely to develop type 2
diabetes compared with patients in the LABD group, with
adjusted hazard ratio (HR) 1.27 (95% CI, 1.07–1.50; P= 0.006).
The results were similar, i.e., increased risk of diabetes onset, in the
subgroup of patients with mild to moderate disease severity
(GOLD A/B), but not in the GOLD C/D subgroup (Fig. 1a).
The risk of diabetes progression was not signiﬁcantly increased
with ICS vs. LABD initiation, either among all matched patients,
with HR 1.04 (0.87–1.25; P= 0.67), nor in GOLD A/B or GOLD C/D
subgroups (Fig. 1b).
There was a non-signiﬁcantly increased risk for osteoporosis
onset among the ICS initiators compared with LABD initiators,
with HR 1.13 (0.93–1.39, P= 0.22), with similar ﬁndings among
GOLD A/B and C/D subgroups and among women and men
analyzed separately (Fig. 1c).
Outcomes by mean daily ICS exposure
The risk of diabetes onset showed a dose–response for mean daily
ICS exposure, with signiﬁcantly increased risk at mean daily
exposures of ≥ 500 µg/day (compared with < 250 µg/day, ﬂutica-
sone propionate–equivalent). A dose–response was evident in
both GOLD A/B and GOLD C/D groups, with signiﬁcantly increased
risk of diabetes onset in GOLD A/B at exposures of ≥ 1000 µg/day
(Fig. 2a).
The risk of diabetes progression also showed a clear
dose–response relationship with mean daily ICS exposure for all
patients and for the GOLD A/B and GOLD C/D subgroups, with
signiﬁcant increase in risk of diabetes progression for all patients
and the GOLD C/D subgroup at exposures of ≥ 500 µg/day and for
the GOLD A/B subgroup at exposures of ≥ 1000 µg/day (Fig. 2b).
We found that the risk of osteoporosis onset also increased with
a clear dose–response for mean daily ICS exposure and
signiﬁcantly increased risk at exposures of ≥ 500 µg/day, with a
similar pattern for the two GOLD subgroups and for women.
Among men, all mean daily exposures were associated with
increased risk that was statistically signiﬁcant except for the
greatest mean daily exposure (≥ 1000 µg/day; Fig. 2c).
Outcomes by cumulative ICS exposure
There was no signiﬁcant increase in adjusted results for risk and
no consistent dose–response effect related to cumulative ICS
exposure for diabetes onset, diabetes progression, or osteo-
porosis onset, either overall (online Supplementary Figs 2–4) or
by GOLD group (data not shown). The results for diabetes
progression showed lower precision, likely because of fewer
patients in the higher cumulative exposure categories (online
Supplementary Fig. 3).
DISCUSSION
The results of this large historical cohort study indicate that ICS
initiation as the ﬁrst maintenance treatment for patients with
COPD is associated with greater risk of developing type 2 diabetes
mellitus as compared with LABD treatment. There was no
conclusive evidence to suggest the same association for diabetes
progression or onset of osteoporosis overall (i.e., when all ICS
doses were considered). However, for patients initiated on ICS,
there were evident dose–response relationships for all three
outcomes with regard to mean daily ICS exposure. We observed
signiﬁcantly greater risk of diabetes onset, diabetes progression,
and osteoporosis onset at mean daily exposures of ≥ 500 µg/day
in ﬂuticasone propionate-equivalents (compared with reference
value of < 250 µg/day). A dose–response relationship was not
evident for cumulative ICS exposures. Importantly from a clinical
perspective, there was considerable use of ICS outside of current
GOLD recommendations, with over half of patients in 2011 GOLD
groups A/B prescribed ICS.
We examined the relationship between ICS use and risk of side
effects in a large COPD population, excluding those with asthma
because ICS therapy for asthma is not contested: ICS are the
D.B. Price et al.
2
npj Primary Care Respiratory Medicine (2019)    38 Published in partnership with Primary Care Respiratory Society UK
1
2
3
4
5
6
7
8
9
0
()
:,;
cornerstone of asthma pharmacologic treatment and their wide-
reaching beneﬁts are well documented.19 Instead the beneﬁts of
ICS for patients with COPD, particularly those with milder disease
(GOLD A/B), and particularly in comparison with LABDs, remain in
question.3,20,21 Our ﬁndings place further doubt with regard to the
risk-beneﬁt ratio for ICS in COPD. Patients with COPD are already
at increased risk of hip fracture, and they are older, hence more
likely to have diabetes, osteopenia, or other comorbidities.2,22
Table 1. Demographic and clinical characteristics of matched patients in the diabetes onset cohort during the baseline year
LABD (n= 6540) ICS (n= 11,430) P valuea SMD (%)b RCC (%)b
Male, n (%) 3835 (58.6) 6788 (59.4) 0.33 1.5 0.0
Age, mean (SD) 68.0 (9.5) 67.7 (9.4) 0.035 3.9 0.3
Index year, median (IQR) 2008 (2006–2011) 2007 (2004–2009) <0.0001 37.3 1.6
Smoking status, available data, n (%) 6479 (99.1) 11,303 (98.9)
Current smoker 2904 (44.8) 4978 (44.0) 0.33 2.3 0.1
Ex-smoker 3269 (50.5) 5823 (51.5)
Never-smoker 306 (4.7) 502 (4.4)
Body mass index, kg/m2, mean (SD) 26.5 (5.4) 26.3 (5.3) 0.083 2.8 4.2
Cardiovascular disease, n (%) 2233 (34.1) 3619 (31.7) 0.0006 5.3 0.4
OCS prescriptions/yr, n (%)c
0 5275 (80.7) 8827 (77.2) <0.0001 8.3 2.1
1 880 (13.5) 1775 (15.5)
2 258 (3.9) 530 (4.6)
≥3 127 (1.9) 298 (2.6)
Antibiotic prescriptions/yr, n (%)d
0 3911 (59.8) 6732 (58.9) 0.151 3.2 0.0
1 1540 (23.5) 2646 (23.1)
2 660 (10.1) 1219 (10.7)
≥3 429 (6.6) 833 (7.3)
FEV1 %predicted, data available 4090 (62.5) 5799 (50.7)
<30% 161 (3.9) 292 (5.0) <0.0001 9.6 9.2
30–49% 900 (22.0) 1568 (27.0)
50–79% 2441 (59.7) 3093 (53.3)
≥80% 588 (14.4) 846 (14.6)
Exacerbations/yr, n (%)d
0 3452 (52.8) 5780 (50.6) 0.0035 5.2 0.0
1 1834 (28.0) 3244 (28.4)
≥2 1254 (19.2) 2406 (21.0)
MRC score available, n (%) 5895 (90.1) 9615 (84.1)
1 832 (14.1) 1405 (14.6) 0.25 0.5 8.7
2 2852 (48.4) 4601 (47.9)
3 1498 (25.4) 2399 (25.0)
4 623 (10.6) 1019 (10.6)
5 90 (1.5) 191 (2.0)
GOLD group data available, n (%) 5895 (90.1) 9615 (84.1)
GOLD A 2476 (42.0) 3807 (39.6) 0.0001 6.6 9.8
GOLD B 1426 (24.2) 2214 (23.0)
GOLD C 1208 (20.5) 2199 (22.9)
GOLD D 785 (13.3) 1395 (14.5)
FEV1 forced expiratory volume in 1 s, GOLD Global Initiative for Chronic Obstructive Lung Disease, ICS inhaled corticosteroid, IQR interquartile range, LABD long-
acting bronchodilator, MRC Medical Research Council dyspnea scale, OCS oral corticosteroid, RCC relative change in coefﬁcient, SMD standardized mean
difference, yr during the baseline year
For baseline variables with missing data, the percentages of patients with available data are noted
aP values shown using Kruskal–Wallis equality-of-populations rank test or Pearson’s χ2-test of independent categories for continuous and categorical variables,
respectively
bAn SMD ≤ 10% indicates sufﬁcient balance between groups. The baseline variables with RCC ≥ 2%, which we deﬁned as indicating bias potential, were
selected for the direct matching attempts
c38 (0.6%) and 69 (0.6%) patients in LABD and ICS groups were receiving maintenance OCS (see Supplementary Table 4)
dAntibiotics were those prescribed on the same day as a lower respiratory consultation (identiﬁed by a Read code for a lower respiratory event) Moderate-to-
severe exacerbations are deﬁned in Methods section
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Our ﬁndings with regard to diabetes onset in these large COPD
cohorts extend earlier observational study ﬁndings in which
patients with COPD were in the minority (only 17% and 22% of
cases and controls, respectively, were considered to have probable
COPD).7 In that study of patients treated for respiratory disease
(asthma and COPD) in 1990 through 2007, a signiﬁcant 34%
increase in rate of diabetes onset was associated with current use of
ICS. In addition, patients who were prescribed oral antidiabetic
Table 2. Demographic and clinical characteristics of matched patients in the diabetes progression cohort during the baseline year
LABD (n= 324) ICS (n= 480) P valuea SMD (%)b RCC (%)b
Male, n (%) 214 (66.0) 319 (66.5) 0.90 0.9 0.0
Age, mean (SD) 70.8 (8.1) 71.1 (7.5) 0.69 6.1 0.8
Index year, median (IQR) 2009 (2007–2011) 2008 (2006–2010) 0.0009 24.0 1.4
Smoking status, available data, n (%) 324 (100.0) 480 (100.0)
Current smoker 119 (36.7) 154 (32.1) 0.38 10.0 0.0
Ex-smoker 188 (58.0) 301 (62.7)
Never-smoker 17 (5.2) 25 (5.2)
Body mass index, kg/m2, mean (SD) 30.4 (5.7) 30.8 (6.4) 0.79 7.6 0.0
Last HbA1c, %, mean (SD) 6.9 (1.1) 6.9 (1.1) 0.79 2.5 0.1
Cardiovascular disease, n (%) 181 (55.9) 259 (54.0) 0.59 3.8 0.0
OCS prescriptions/yr, n (%)c
0 275 (84.9) 388 (80.8) 0.33 13.8 0.1
1 37 (11.4) 63 (13.1)
2 9 (2.8) 18 (3.8)
≥ 3 3 (0.9) 11 (2.3)
Antibiotic prescriptions/yr, n (%)d
0 191 (59.0) 276 (57.5) 0.72 8.3 0.8
1 86 (26.5) 120 (25.0)
2 30 (9.3) 53 (11.0)
≥ 3 17 (5.2) 31 (6.5)
FEV1 %predicted, data available 224 (69.1) 283 (59.0)
<30% 7 (3.1) 9 (3.2) 0.69 10.8 15.5
30–49% 49 (21.9) 72 (25.4)
50–79% 132 (58.9) 165 (58.3)
≥ 80% 36 (16.1) 37 (13.1)
Exacerbations/yr, n (%)d
0 175 (54.0) 245 (51.0) 0.48 8.8 2.3
1 95 (29.3) 139 (29.0)
≥ 2 54 (16.7) 96 (20.0)
MRC score available, n (%) 307 (94.8) 459 (95.6)
1 37 (12.1) 62 (13.5) 0.97 5.5 1.9
2 136 (44.3) 194 (42.3)
3 86 (28.0) 128 (27.9)
4 40 (13.0) 63 (13.7)
5 8 (2.6) 12 (2.6)
GOLD group data available, n (%) 307 (94.8) 459 (95.6)
GOLD A 118 (38.4) 169 (36.8) 0.83 6.9 1.7
GOLD B 85 (27.7) 120 (26.1)
GOLD C 55 (17.9) 87 (19.0)
GOLD D 49 (16.0) 83 (18.1)
FEV1 forced expiratory volume in 1 s, GOLD Global Initiative for Chronic Obstructive Lung Disease, ICS inhaled corticosteroid, IQR interquartile range, LABD long-
acting bronchodilator, MRC Medical Research Council dyspnea scale, OCS oral corticosteroid, RCC relative change in coefﬁcient, SMD standardized mean
difference, yr during the baseline year
aP values shown using Kruskal–Wallis equality-of-populations rank test or Pearson's χ2-test of independent categories for continuous and categorical variables,
respectively
bAn SMD ≤ 10% indicates sufﬁcient balance between groups. The baseline variables with RCC ≥ 2%, which we deﬁned as indicating bias potential, were
selected for the direct matching attempts
c1 (0.3%) and 2 (0.4%) patients in LABD and ICS groups were receiving maintenance OCS (see Supplementary Table 5)
dAntibiotics were those prescribed on the same day as a lower respiratory consultation (identiﬁed by a Read code for a lower respiratory event). Moderate-to-
severe exacerbations are deﬁned in Methods section
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agents experienced a signiﬁcant 34% increase in rate of diabetes
progression to insulin therapy associated with ICS therapy.7 Instead,
our ﬁndings did not reach statistical signiﬁcance for the comparison
between ICS and LABD for diabetes progression, for which post hoc
power calculations indicated slightly lower analytical power than for
the other comparisons. However, similar to the earlier ﬁndings, our
study detected a dose–response effect of mean daily ICS exposure
for diabetes progression as well as onset.
With regard to osteoporosis onset, prior studies of ICS therapy
for COPD have used bone mineral density or fracture as
Table 3. Demographic and clinical characteristics of matched patients in the osteoporosis onset cohort during the baseline year
LABD (n= 7279) ICS (n= 12,619) P valuea SMD (%)b RCC (%)b
Male, n (%) 4517 (62.1) 7893 (62.5) 0.48 1.0 0.0
Age, mean (SD) 67.9 (9.4) 67.7 (9.3) 0.034 3.8 0.0
Index year, median (IQR) 2008 (2006–2011) 2007 (2004–2009) <0.0001 38.1 1.3
Smoking status, available data, n (%) 7214 (99.1) 12,484 (98.9)
Current smoker 3161 (43.8) 5394 (43.2) 0.47 1.8 0.1
Ex smoker 3717 (51.5) 6537 (52.4)
Never smoker 336 (4.7) 553 (4.4)
Body mass index, kg/m2, mean (SD) 27.1 (5.6) 27.1 (5.6) 0.007 3.0 0.4
Cardiovascular disease, n (%) 2663 (36.6) 4343 (34.4) 0.0020 4.6 0.4
OCS prescriptions/yr, n (%)c
0 5880 (80.8) 9768 (77.4) <0.0001 8.4 0.6
1 977 (13.4) 1950 (15.5)
2 286 (3.9) 570 (4.5)
≥ 3 136 (1.9) 331 (2.6)
Antibiotic prescriptions/yr, n (%)d
0 4375 (60.1) 7440 (59.0) 0.034 3.9 0.0
1 1709 (23.5) 2911 (23.1)
2 726 (10.0) 1340 (10.6)
≥ 3 469 (6.4) 928 (7.4)
FEV1 %predicted, data available 4544 (62.4) 6431 (51.0)
< 30% 167 (3.7) 324 (5.0) <0.0001 10.2 7.6
30–49% 992 (21.8) 1704 (26.5)
50–79% 2741 (60.3) 3491 (54.3)
≥ 80% 644 (14.2) 912 (14.2)
Exacerbations/yr, n (%)d
0 3867 (53.1) 6392 (50.7) 0.0011 5.4 0.0
1 2019 (27.7) 3587 (28.4)
≥ 2 1393 (19.1) 2640 (20.9)
MRC score available, n (%) 6567 (90.2) 10,635 (84.3)
1 912 (13.9) 1548 (14.6) 0.108 0.2 8.1
2 3135 (47.7) 5070 (47.7)
3 1731 (26.4) 2647 (24.9)
4 678 (10.3) 1164 (10.9)
5 111 (1.7) 206 (1.9)
GOLD group data available, n (%) 6567 (90.2) 10,635 (84.3)
GOLD A 2741 (41.7) 4203 (39.5) <0.0001 5.9 7.9
GOLD B 1623 (24.7) 2490 (23.4)
GOLD C 1306 (19.9) 2415 (22.7)
GOLD D 897 (13.7) 1527 (14.4)
FEV1 forced expiratory volume in 1 s, GOLD Global Initiative for Chronic Obstructive Lung Disease, ICS inhaled corticosteroid, IQR interquartile range, LABD long-
acting bronchodilator, MRC Medical Research Council dyspnea scale, OCS oral corticosteroid, RCC relative change in coefﬁcient, SMD standardized mean
difference, yr during the baseline year
aP values shown using Kruskal–Wallis equality-of-populations rank test or Pearson’s χ2-test of independent categories for continuous and categorical variables,
respectively
bAn SMD ≤ 10% indicates sufﬁcient balance between groups. The baseline variables with RCC ≥ 2%, which we deﬁned as indicating bias potential, were
selected for the direct matching attempts
c38 (0.6%) and 69 (0.6%) patients in LABD and ICS groups were receiving maintenance OCS (see Supplementary Table 6)
dAntibiotics were those prescribed on the same day as a lower respiratory consultation (identiﬁed by a Read code for a lower respiratory event). Moderate-to-
severe exacerbations are deﬁned in Methods section
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outcomes.11,12,23,24 Instead, we elected to study onset to the ﬁrst
recorded diagnosis of osteoporosis, a diagnosis that is associated
with increased risk of fracture. The lack of signiﬁcantly increased
risk when comparing ICS use with LABD use may be of limited
relevance, as the ICS group was populated with patients with a
mixture of exposure levels, which may have diluted the real effect
of ICS exposure on the onset of osteoporosis. Indeed, we observed
clear evidence of dose–response on the onset of osteoporosis for
mean daily ICS exposure, beginning at ≥ 500 µg/day (vs. <250 µg/
day) for all patients and for both women and men. However, the
rationale for the diagnosis of osteoporosis (e.g., dual-energy x-ray
absorptiometry vs. fragility fracture) was not documented, thus
the clinical signiﬁcance of the diagnosis may vary based on how
the disease was revealed. Conversely, patients could have had
undiagnosed osteoporosis, leading to an underestimation of ICS
effects on osteoporosis onset.
Interestingly, we observed the adverse effects of ICS therapy in
relation to mean daily exposure but not cumulative exposure.
Corticosteroids increase the risk of diabetes in part by increasing
insulin resistance, which allows blood glucose levels to rise;25 and
corticosteroids affect bone turnover by enhancing bone resorp-
tion and decreasing bone formation.26 Signiﬁcant decreases in
levels of osteocalcin, a marker of bone formation, have been
recorded in patients with COPD prescribed long-term therapy with
inhaled beclomethasone dipropionate.27 These systemic effects
would be more likely at the higher systemic exposures that occur
at higher doses of ICS, as evidenced by studies demonstrating
systemic effects and dose–response of systemic effects with ICS
administration.21,28–30 We hypothesized that the mean daily
exposure reﬂected the real intensity of treatment (i.e., resulting
in effects on metabolism and bone formation), as opposed to high
cumulative exposure, which could be the result of long-term but
low daily exposures, hence resulting in fewer systemic effects.
Indeed, the relation between cumulative exposure and onset of
diabetes or osteoporosis was the reverse of what was expected:
the greatest ICS cumulative exposure stratum showed the lowest
rates of diabetes and osteoporosis onset. This is likely owing to
inverse causation, as the cumulative exposure measure has a
function of time incorporated. The patients with longer follow-up
have lower likelihoods to develop the disease but they
accumulate ICS.
We believe this study has several important strengths relative to
prior work, including both prior observational studies and
randomized controlled trials. We employed two large well-
regarded databases, tapping into big numbers of patients and
data over a long time period that enabled us to identify true
initiators of therapy for COPD (i.e., with long baseline periods
without COPD therapy) and to follow them for several years, much
longer than possible in most randomized controlled trials. The
coding of COPD is reliably recorded in the databases, especially
since 2004 and the start of the UK Quality Outcomes Framework,
which is when most of our study patients initiated COPD
maintenance therapy.31 We employed multiple approaches for
handling confounding by combining direct matching with a
propensity score, plus adjustment for residual confounding after
matching as well as adjustment for time-varying exposure to oral
corticosteroids (OCS). Although we did not speciﬁcally exclude
patients who were on maintenance OCS, we did indeed exclude
any patient prescribed ﬁve or more OCS prescriptions during any
study year, which effectively excludes maintenance OCS therapy
as most UK prescriptions are for 1 month of treatment. Our
rationale for minimizing the inclusion of patients on maintenance
OCS in the study was because statistical adjustments, even with
time-varying exposure measures, have their limitations. Therefore,
we covered this possible confounding effect of OCS by both
precise statistical adjustment, as well as by restriction to fewer
than ﬁve OCS courses per year.
Using electronic medical record data instead of claims data
provided the high granularity of information that enabled us to
model three aspects of ICS exposure, including ICS vs. LABD, mean
daily ICS exposure, and cumulative exposure. Moreover, the mean
daily exposure variable served to support adherence with ICS
therapy as it was calculated using prescribing data, considered
reliable in the CPRD.32 Finally, we studied a patient population
representative of patients seen in routine clinical practice rather
than those enrolled in randomized controlled trials, which tend to
include younger patients and more men than women.33
Approximately half of patients in our study had experienced a
COPD exacerbation during the baseline year, similar to the 53%
reported in a recent study of the natural history of COPD
exacerbations.34
Median follow-up times in each study group were over 3.5 years
and tended to be longer in the ICS group than the LABD group of
each study cohort (4.9–5.6 vs. 3.7–4.7 years, respectively). Patients
prescribed ICS could receive concomitant LABD and remain in the
outcome analyses. However, follow-up ended for patients in the
LABD group if they were prescribed ICS, and one could speculate
that patients initiated on ICS may have exacerbated, also needing
OCS, although we did not follow them beyond the time of ICS
initiation. In a prior study,16 a big driver of therapy change was
exacerbations, which could explain the relatively long follow-up in
each treatment group of each study cohort because approxi-
mately two-thirds of patients with available GOLD group data in
each group were in GOLD A or B.
A study limitation is that the databases include information
collected for clinical use rather than speciﬁcally for research
purposes, and some information is not reliably included, such as
hospitalizations and emergency department visits.35 Moreover,
the diabetes progression cohort was relatively small. One study
found that rates of diabetes and musculoskeletal conditions were
underestimated in the CPRD;36 however, we do not expect this
under-registration to be different for the ICS and LABD treatment
groups, and therefore comparative effects should not be biased.
Another factor that could have led to an underestimation of ICS
effects is the decision to adopt the conservative approach of
analyzing data beginning at 1.5 years after ICS/LABD initiation.
It would have been of interest to examine diabetes onset during
that 1.5-year period, and this remains a topic for further study.
Moreover, analyses excluding patients who received any OCS
prescription, as well as analyses examining OCS safety in COPD,
are of great interest for future work.
Table 4. Available patient data: number of years before index date and during follow-up expressed as median (interquartile range)
Diabetes onset cohort Diabetes progression cohort Osteoporosis onset cohort
Years LABD (N= 6540) ICS (N= 11,430) LABD (N= 324) ICS (N= 480) LABD (N= 7279) ICS (N= 12,619)
Baseline 17.0 (8.7–31.9) 15.6 (8.0–29.6) 17.5 (9.3–31.8) 16.4 (9.5–33.9) 17.0 (8.6–31.8) 15.6 (8.0–29.6)
Outcomea 4.7 (2.7–5.2) 5.6 (3.6–8.1) 3.8 (2.8–5.3) 4.9 (3.1–6.8) 3.7 (2.7–5.2) 5.5 (3.6–8.1)
ICS inhaled corticosteroid, LABD long-acting bronchodilator
aIncluding the ﬁrst 1.5 years when outcome events were not assessed
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As for all observational studies there remains the potential for
unmeasured confounding. Our analyses were limited to the
available data, which precluded the inclusion of some potential
confounding factors, such as socioeconomic status, physician
characteristics, and details of disease severity, including spirome-
try results. Although the level of patients’ physical activity, a driver
of both type 2 diabetes and osteoporosis, was not available, we
note that Medical Research Council dyspnea scale scores were
available for most patients and were not signiﬁcantly difference
between treatment cohorts. Finally, another limitation could relate
to the long timespan of the study, which is likely associated with
time-related heterogeneity of patients’ clinical characteristics and
treatments. However, the impact of this heterogeneity is limited
by the matching process.
The proportions of patients in GOLD A/B groups prescribed ICS
(60% or more) was similar to other studies in the United
Kingdom.16,17 Discrepancies between COPD treatment recom-
mendations and prescribing practices for ICS in COPD have been
described also from other countries in Europe and North
America.15,37 We would note, however, that we are using 2011
GOLD groups to categorize prescribing practices dated predomi-
nantly from 2004–2011. A recent study reports that by 2015 in the
UK, ICS-containing ﬁrst maintenance therapy for 2011 GOLD A/B
COPD had declined to 47%;17 in addition, ICS monotherapy
prescriptions have declined with time in the UK, and long-acting
muscarinic antagonists (LAMA) prescriptions have increased with
time.16 (The ﬁrst LAMA was licensed in the UK in 2002).
We observed a clear dose–response relationship between mean
daily exposure to ICS and increased risk for diabetes onset,
diabetes progression, and osteoporosis onset for patients with
COPD in this large matched cohort study. Long-term ICS therapy
for COPD at mean ICS exposures of 500 µg/day or greater (vs. <
250 µg/day, ﬂuticasone propionate-equivalent) is associated with
an increased risk of diabetes, diabetes progression, and osteo-
porosis. In addition, we found considerable use of long-term
medium- to high-dose ICS therapy outside of current GOLD
strategy recommendations, prescribing practices that expose
patients to increased risks for serious adverse effects. Our ﬁndings
support the importance of careful selection of COPD therapies and
prescribing ICS only when indicated and at the lowest possible
doses. Moreover, these ﬁndings support current GOLD recom-
mendations for prescribing ICS selectively to patients with
frequent COPD exacerbations despite optimal bronchodilator
therapy.
METHODS
Data sources
This historical matched cohort study used data from the Clinical Practice
Research Datalink (CPRD) and the Optimum Patient Care Research
Database (OPCRD), two large, well-managed UK databases containing
anonymized, longitudinal medical record data drawn from general
practices, which serve as central locations for medical records in the
UK.38,39 The CPRD contains medical record data for about ﬁve million
patients from over 600 subscribing practices and has long been used for
pharmacoepidemiological research.32,39,40 The OPCRD is a database
developed to improve patient outcomes through medical research and
services, with focus on patient-reported outcomes, that, at the time of this
study, contained anonymous data for over 2.4 million patients from over
576 primary care practices across the United Kingdom.38 The OPCRD has
been reviewed and ethically approved by the NHS Health Research
Authority to hold and process anonymized data as part of service delivery
(Research Ethics Committee reference: 15/EM/0150). We used Quality
Outcome Framework (QOF) diagnostic Read codes, which are part of the
UK national quality improvement initiative and pay-for-performance
scheme. The diagnostic and prescribing information in the CPRD has
been evaluated and is considered to be reliable, particularly since the
introduction in 2004 of QOF, which provides incentives for practitioners to
conduct diagnostic screening and recording for COPD and other
diseases.31
The study was conducted according to recommendations for observa-
tional research.41 The protocol was approved by the CPRD Independent
Scientiﬁc Advisory Committee (ISAC reference number 16_040) and the
Anonymised Data Ethics Protocols and Transparency committee (ADEPT
Fig. 1 Hazard ratios (95% CIs) for matched inhaled corticosteroid
(ICS) vs. long-acting bronchodilator (LABD) initiators, all patients and
stratiﬁed by GOLD group, for a diabetes onset, b diabetes
progression, and c osteoporosis onset (See Methods section for
lists of variables used for adjustment in the outcome models.)
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Approval Reference ADEPT1316), the independent scientiﬁc advisory
committee for the OPCRD.38 The study was registered with the European
Network Centres for Pharmacoepidemiology and Pharmacovigilance
(ENCePP), European Union electronic Register of Post-Authorisation
Studies (EU PAS Register number 13218).42,43 No patient identifying
information was accessible during the study.
The CPRD and OPCRD data sets were constructed separately and
checked for overlap, before pooling for analyses, in order to exclude
duplicate patients. Identiﬁcation of patients who were present in both data
sets was conducted by matching on a number of variables, such as the
year of birth, sex, and index date. During this process, patients were never
identiﬁable and the data analysts who constructed the data sets had no
access to any data in a patient identiﬁable form. The rationale for
combining CPRD and OPCRD data sets was to increase the number of
patients included in the study groups and therefore increase the power to
detect clinically relevant differences between treatment cohorts. Together,
the data sets comprised medical record information spanning from 1983 to
May 2016.
Study design and patients
Eligible patients had a record of physician-diagnosed COPD, were aged 40
years or older when prescribed their ﬁrst ICS or LABD maintenance therapy
for COPD, and had continuous medical records for a ≥ 1-year baseline
period before the index date (ﬁrst COPD maintenance therapy), followed
by an outcome period of ≥ 2 years (Fig. 3). Patients were required to have
no recorded diagnosis of asthma or to have an asthma-resolved code
recorded after the asthma diagnostic code and before the index date. In
addition, eligible patients had to receive two or more respiratory
prescriptions (ICS or LABD, depending on treatment group) during each
outcome year and be prescribed less than ﬁve OCS prescriptions during
each study year. In the United Kingdom, the prescribed dose for an acute
course of OCS is variable but prednisone 30–40mg per day for 5 days is
usual. The index date range was January 1990 to August 2015.
Patients were assigned to the ICS or LABD treatment group according to
their ﬁrst COPD prescription and were followed from the index date to the
ﬁrst outcome event, the end of available data, the end of ICS use (ICS
group) or the initiation of ICS (LABD group), whichever occurred ﬁrst.
Patients initiating ICS (the ICS group) had no previous prescriptions for
LABA, LAMA, or combination LABA/LAMA and had received two or more
ICS prescriptions during at least 2 outcome years. Prescribing of LABD was
permitted in the ICS group, and the prescribed ICS drug and/or inhaler
could change during the outcome period; the study observation period
ended if ICS were stopped. Patients initiating LABD therapy as LABA,
LAMA, or combination LABA/LAMA (LABD group) had no previous ICS
prescriptions; the LABD drug(s) could change during outcome, and the
study observation period ended if ICS were prescribed. Patients in the ICS
and LABD groups were unique, i.e., patients did not contribute data to
both cohorts.
We compared outcomes for the two treatment groups within three
unique study cohorts with speciﬁc eligibility criteria designed to capture:
(1) the onset of diabetes (diabetes onset cohort), (2) the progression of
diabetes (diabetes progression cohort), and (3) the onset of osteoporosis
(osteoporosis onset cohort). Eligibility criteria speciﬁc to each cohort are
summarized in Table 5. The diabetes onset cohort included patients with
no prior recorded type 2 diabetes mellitus diagnosis and/or antidiabetic
treatment, and not more than one HbA1c reading of > 6.5%, ever before
the index date or within 1.5 years after the index date. A prior diagnosis of
type 1 diabetes mellitus ever before the index date was also cause for
exclusion. Patients prescribed metformin for physician-diagnosed poly-
cystic ovary syndrome were not excluded. The diabetes progression cohort
included patients with recorded diagnosis and/or treatment for type 2
diabetes mellitus and/or two or more HbA1c readings > 6.5% ever before
the index date. In addition, included patients had one or more HbA1c
recorded readings in both the baseline year and the outcome period
starting at 1.5 years after the index date. Exclusion criteria for the diabetes
progression cohort were a recorded diabetes-resolved code after the
diabetes diagnostic code, physician-diagnosed type 1 diabetes mellitus
ever before the index date, and physician-diagnosed polycystic ovary
syndrome with one or more metformin prescriptions before the index
date. The osteoporosis onset cohort included patients with no prior
recorded osteoporosis diagnosis ever before the index date or within 1.5
years after the index date.
GOLD (C+D), <250 (reference) (N = 860)
GOLD (C+D), 250-499 (N = 822)
GOLD (C+D), 500-999 (N = 1,130)
GOLD (C+D), 1000 (N = 782)
GOLD (A+B), <250 (reference) (N = 1920)
GOLD (A+B), 250-499 (N = 1479)
GOLD (A+B), 500-999 (N = 1625)
GOLD (A+B), 1000 (N = 997)
All patients, <250 (reference) (N = 3465)
All patients, 250-499 (N = 2768)
All patients, 500-999 (N = 3203)
All patients, 1000 (N = 1994)
1.00 (1.00–1.00)
1.21 (0.76–1.93)
1.23 (0.77–1.97)
1.28 (0.83–1.97)
1.31 (0.84–2.05)
1.39 (0.89–2.18)
1.43 (0.90–2.26)
1.00 (1.00–1.00)
1.05 (0.78–1.41)
1.16 (0.85–1.57)
1.03 (0.77–1.38)
1.20 (0.89–1.63)
1.26 (0.93–1.70)
1.54 (1.12–2.11)
1.00 (1.00–1.00)
1.07 (0.86–1.33)
1.17 (0.94–1.46)
1.11 (0.90–1.37)
1.27 (1.02–1.59)
1.27 (1.01–1.59)
1.50 (1.18–1.90)
Better  Worse
0.7 0.8 0.9 1 1.2
5 1.5 1.7
5 2
2.2
5
Hazard ratio
a
GOLD (C+D), <250 (reference) (N = 25)
GOLD (C+D), 250-499 (N = 28)
GOLD (C+D), 500-999 (N = 39)
GOLD (C+D), 1000 (N = 78)
GOLD (A+B), <250 (reference) (N = 59)
GOLD (A+B), 250-499 (N = 57)
GOLD (A+B), 500-999 (N = 62)
GOLD (A+B), 1000 (N = 111)
All patients, <250 (reference) (N = 91)
All patients, 250-499 (N = 92)
All patients, 500-999 (N = 103)
All patients, 1000 (N = 194)
1.00 (1.00–1.00)
1.44 (0.63–3.30)
1.47 (0.64–3.39)
2.19 (1.00–4.79)
2.49 (1.12–5.53)
2.38 (1.13–5.01)
2.83 (1.30–6.17)
1.00 (1.00–1.00)
1.15 (0.69–1.92)
1.18 (0.68–2.04)
1.42 (0.87–2.33)
1.42 (0.83–2.40)
2.21 (1.42–3.43)
2.55 (1.62–4.00)
1.00 (1.00–1.00)
1.37 (0.91–2.07)
1.38 (0.91–2.11)
1.67 (1.12–2.50)
1.69 (1.12–2.56)
2.36 (1.63–3.41)
2.54 (1.74–3.71)
Better  Worse
0.7 0.8 0.9 1 1.5 2 2.5 3 4 5 6 7
Hazard ratio
b
Female, <250 (reference) (N = 1480)
Female, 250-499 (N = 1145)
Female, 500-999 (N = 1317)
Female, 1000 (N = 784)
Male, <250 (reference) (N = 2423)
Male, 250-499 (N = 1931)
Male, 500-999 (N = 2211)
Male, 1000 (N = 1328)
GOLD (C+D), <250 (reference) (N = 970)
GOLD (C+D), 250-499 (N = 915)
GOLD (C+D), 500-999 (N = 1222)
GOLD (C+D), 1000 (N = 835)
GOLD (A+B), <250 (reference) (N = 2168)
GOLD (A+B), 250-499 (N = 1664)
GOLD (A+B), 500-999 (N = 1805)
GOLD (A+B), 1000 (N = 1056)
All patients, <250 (reference) (N = 3903)
All patients, 250-499 (N = 3076)
All patients, 500-999 (N = 3528)
All patients, 1000 (N = 2112)
1.00 (1.00–1.00)
1.04 (0.73–1.48)
1.12 (0.78–1.60)
1.85 (1.37–2.51)
2.02 (1.48–2.76)
1.57 (1.11–2.22)
1.73 (1.22–2.46)
1.00 (1.00–1.00)
1.71 (0.99–2.94)
1.82 (1.02–3.24)
1.71 (1.00–2.91)
1.85 (1.02–3.35)
1.69 (0.91–3.16)
1.87 (0.97–3.60)
1.00 (1.00–1.00)
1.94 (0.95–3.95)
2.15 (1.03–4.49)
2.97 (1.55–5.69)
3.42 (1.73–6.76)
2.84 (1.42–5.65)
3.27 (1.57–6.81)
1.00 (1.00–1.00)
0.83 (0.55–1.24)
0.87 (0.58–1.30)
1.38 (0.98–1.96)
1.47 (1.03–2.11)
1.42 (0.96–2.09)
1.50 (1.02–2.21)
1.00 (1.00–1.00)
1.20 (0.89–1.61)
1.29 (0.96–1.75)
1.76 (1.35–2.29)
1.97 (1.49–2.60)
1.56 (1.15–2.11)
1.76 (1.29–2.39)
Better  Worse
0.7 0.8 0.9 1 1.5 2 2.5 3 4 5 6 7
Hazard ratio
c
Fig. 2 Hazard ratios (95% CIs) for mean daily inhaled corticosteroid
(ICS) exposure (µg/day, vs. reference value of < 250 µg/day), all
patients and stratiﬁed by GOLD group, for a diabetes onset,
b diabetes progression, and also stratiﬁed by sex for c osteoporosis
onset. (See Methods section for lists of variables used for adjustment
in the outcome models)
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We categorized patients into 2011 GOLD groups A, B, C, or D18 using
number of moderate-to-severe exacerbations (at least 15 days apart) during
the baseline year together with values recorded closest to and within 5 years
before the index date for the Medical Research Council (MRC) dyspnea scale
(scored from 1 to 5, with 5 representing the worst dyspnea) and forced
expiratory volume in 1 s (FEV1). Exacerbations during the baseline year were
deﬁned as occurrence of COPD-related unscheduled hospital admission or
accident & emergency attendance; or prescription of an acute course of OCS;
or prescription of antibiotics on the same day as a lower respiratory
consultation (identiﬁed by a Read code for a lower respiratory event). Hence
the GOLD groups were deﬁned as follows:
● GOLD A: MRC score 1–2 and FEV1 ≥ 50% and ≤ 1 COPD exacerbation
with no hospitalization required for COPD.
Fig. 3 Study design. CPRD Clinical Practice Research Datalink, OPCRD Optimum Patient Care Research Database
Table 5. Key eligibility criteria and outcome deﬁnitions speciﬁc to each of the three study cohorts
1. Diabetes onset cohort
Exclusion criteria:
Prior recorded type 2 diabetes mellitus diagnosisa and/or antidiabetic treatment and/or two or more HbA1c readings of > 6.5%, ever before or
within 1.5 years after the index date
Diagnosis of type 1 diabetes mellitus ever before the index date
Outcome deﬁnition of diabetes onset:
Diagnosis of type 2 diabetes mellitus and/or
Antidiabetic drug prescription(s), and/or
At the time of the second of two or more HbA1c readings of > 6.5%
2. Diabetes progression cohort
Inclusion criteria:
Diagnosis and/or treatment for type 2 diabetes mellitus and/or ≥2 HbA1c readings >6.5% ever before the index date
One or more HbA1c readings in both the baseline year and the outcome period starting at 1.5 year after the index date
Exclusion criteria:
Recorded diabetes-resolved code after the diagnostic code, diagnosis of type 1 diabetes mellitus ever before the index date, and diagnosis of
polycystic ovary syndrome with one or more metformin prescriptions ever before the index date
Outcome deﬁnition of diabetes progression (includes worsening disease control)
Increase in HbA1c readings of 0.5% and greater from baseline to outcome period, and/or
Prescription for an increase in daily dose of glucose-regulating drug, excluding increases at the index date or within 3 months of the index
date, and/or
Addition of a new class of glucose-regulating drug without another class being discontinued, and/or
Progression of treatment to insulin from index date to outcome period, in patients without insulin prescriptions in baseline
3. Osteoporosis onset cohort
Exclusion criterion:
Prior recorded osteoporosis diagnosis ever before the index date or within 1.5 year after the index date
Outcome deﬁnition of osteoporosis onset
Diagnosis of osteoporosis
aDiagnoses were deﬁned as recorded diagnostic Read codes. All code lists are available on request
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● GOLD B: MRC score ≥ 3 and FEV1 ≥ 50% and ≤ 1 COPD exacerbation
with no hospitalization required for COPD.
● GOLD C: MRC score 1–2 and FEV1 < 50% and/or ≥ 2 COPD
exacerbations or ≥ 1 exacerbation leading to hospital admission.
● GOLD D: MRC score ≥ 3 and FEV1 < 50% and/or ≥ 2 COPD exacerba-
tions or ≥ 1 exacerbation leading to hospital admission.
Study endpoints
The exposures of interest were (1) ICS as compared with LABDs, (2) mean
daily ICS exposure (µg/day, all prescribed ICS divided by number of follow-
up days), and (3) cumulative ICS exposure (mg, total dose over the follow-
up period).
Time at risk of an outcome event was assessed beginning at 1.5 years
after the index date.8 Patients with diabetes onset or osteoporosis onset
occurring within 1.5 years after the index date were excluded from the
respective study cohorts, and diabetes progression measures were not
counted in that time frame for the diabetes progression cohort based on
the clinical decision that cases within 1.5 years of index date could not be
attributed to ICS initiation and would therefore bias the conclusions.
Onset of diabetes was deﬁned as type 2 diabetes mellitus diagnosis and/
or antidiabetic drug prescriptions, and/or two or more HbA1c readings >
6.5%. Patients with physician-diagnosed polycystic ovary syndrome and
one or more metformin prescriptions in the outcome period were
excluded from the analysis.
Diabetes progression was deﬁned as worsening disease control or
treatment changes indicating disease progression. Worsening disease
control was measured by change in blood glucose level, deﬁned as
increased HbA1c readings of 0.5% and higher, considered to be a clinically
signiﬁcant change.44,45 Change in HbA1c from the baseline year to the ﬁrst
HbA1c reading after 1.5 years after the index date was compared between
the ICS and LABD groups. Disease progression was deﬁned as any of three
types of treatment change:
1. Dose increase of glucose-regulating drug prescription: deﬁned as an
increase in the prescribed daily dose of any glucose-regulating drug
prescribed to the patient. Dose increases at the index date or within
3 months of the index date were not considered to be disease
progression because physicians may increase the dose of glucose-
regulating drugs owing to the known impact of initiating
corticosteroids on glucose levels.
2. Addition of a glucose-regulating drug class: deﬁned as a new drug
class started without another class being discontinued. Oral glucose-
regulating drugs were categorized into six classes: (i) sulfonylureas,
(ii) metformin, (iii) acarbose, (iv) thiazolidinediones, (v) dipeptidyl
peptidase 4 (DPP-4) inhibitors, and (vi) other oral drugs.
3. Progression of treatment to insulin: time between index date and
ﬁrst prescription of insulin in outcome period, in patients without
insulin prescriptions in baseline.
Osteoporosis onset was deﬁned as a diagnostic Read code for
osteoporosis. Osteoporosis drug prescriptions without an accompanying
diagnostic code were not considered indicative of osteoporosis because
commonly prescribed osteoporosis drugs are prescribed for osteopenia
and for other conditions (e.g., bisphosphonates for patients with Paget’s
disease, bone metastasis, or multiple myeloma and strontium for patients
with certain forms of cancer).
We also conducted per-protocol comparisons among different ICS
formulations and inhalers; however, the comparisons were underpowered
and uninterpretable, hence are not reported here.
Cohort matching
We matched patients in the ICS and LABD treatment groups using a mixed
matching process at ratios of 1:1 to 3:1. Patients were matched on a set of
baseline characteristics identiﬁed and predeﬁned by expert judgment as
well as a propensity score created with baseline variables showing relevant
bias, evaluated using the standardized mean difference (SMD)46 in
combination with the bias potential.47
First, a characterization of all baseline demographics, comorbidities,
indicators of disease severity, and other patient-related variables was
carried out for each treatment group within each study cohort. The
difference between treatment groups was quantiﬁed using the SMD.46 This
measure is not affected by the number of observations and is thus a better
way to judge imbalance than a P value of a hypothesis test of difference. It
also provides insight into the magnitude of the difference. The SMD was
calculated for both continuous and categorical variables. An SMD of ≤ 10%
was judged to indicate sufﬁcient balance between the treatment (ICS) and
reference (LABD) groups.
Bias potential was measured using the relative change in coefﬁcient
(RCC), also known as the change-in-estimate, of the exposure when the
covariate was added into the model predicting outcome. Bias potential
assesses the degree to which the observed association between the
exposure of interest and the outcome is affected by conditioning on the
variable.47,48 The baseline variables with RCC ≥ 2%, which we deﬁned as
indicating bias potential, were selected for the direct matching attempts.
Missing data were treated as missing completely at random and were
not imputed. Variables with > 10% of missing data were not considered for
matching and/or the generation of the propensity score. Variables with
missingness of ≤ 10% were encoded into categorical variables, adding a
category for the observations with missing values, enabling these variables
to be used for matching and/or propensity score generation.
Exact matching for categorical variables and matching within a
maximum caliper (maximum distance allowed between a case and a
control) for continuous variables was used to match patients using nearest
neighbor variable mixed matching with a match maximum of 3:1 without
replacement. Mixed matching is a process that helps to utilize more of the
data by matching varying numbers of patients in the control group to each
patient in the treatment group. In other words, there was a group of
unique patients matched 1:1, another group of unique patients matched
1:2, and a third group of unique patients matched 1:3. The analysis was
conducted using all of the matched patients although some patients had
one match whereas other patients had three matches.
The following variables (±their caliper) were used for matching:
1. Year of index date ± 2 years
2. Age ± 5 years
3. Sex
4. Smoking status
5. BMI category (except diabetes progression cohort)
6. Number of exacerbations (recorded as Read code) in the baseline
year, categorized
Attempted direct matching in the diabetes progression cohort found
that only 50% of patients were matchable with the direct matching criteria;
therefore, BMI was not used for direct matching in that cohort but was
instead included as part of the propensity score.
The propensity score was generated using a logistic regression model
with the variables listed in Table 6. The caliper used for the propensity
score during matching was 0.25 times its standard deviation.49
For each outcome cohort, 20 matching runs with different random
patient orders were made to select the best combination of number of
matched patients and multivariable balance statistics. The statistics used
were as follows:
● Number of cases (ICS initiators) matched.
● C-statistics of the prediction model of exposure using all variables with
< 10% missing values, in the matched. This is a measure of
discriminative ability of the set of 35 baseline characteristics for
exposure.
● Percentage of variables of the 35 baseline characteristics used to
generate the propensity score that achieved residual bias potential < 1
and < 0.5%.
Statistical analyses
For tests of differences at baseline, we used the Kruskal–Wallis equality-of-
populations rank test and Pearson’s χ2-test of independent categories for
continuous and categorical variables, respectively.
We used conditional proportional hazards regression, adjusting for
residual confounding, to compare ICS vs. LABD and to model ICS
exposures for time-to-event outcomes. Mean effects and their 95%
conﬁdence intervals (CIs) and two-sided p values were calculated for all
patients and stratiﬁed by 2011 GOLD groups A/B and C/D.18
We adjusted for variables with residual confounding (causing at least 2%
RCC). In addition, adjusted models also included age, sex, and two time-
varying covariates representing exposure to OCS over time. For each
365 days of the follow-up period, the number of OCS prescriptions was
calculated, as well as the cumulative number of OCS prescriptions until
that follow-up year.
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Assumptions for regression models were assessed as appropriate.
Additional variables used for adjustment in the outcome models
comparing matched ICS vs. LABD treatment groups were as follows:
● For the diabetes onset cohort: number of OCS prescriptions;
● For the diabetes progression cohort: number of moderate-severe
exacerbations and years since type 2 diabetes diagnosis;
● For the osteoporosis onset cohort: none.
Within the ICS group only, we analyzed mean daily ICS exposure
compared with the reference value of < 250 µg/day in ﬂuticasone
propionate-equivalents and cumulative ICS exposure compared with
reference value of < 50mg in ﬂuticasone propionate-equivalents. The
within-ICS treatment group comparisons (split by ICS mean daily exposure
and by ICS cumulative exposure) were restricted to the patients who were
matched to LABD group patients in order to facilitate comparisons of
results with those from the ICS vs. LABD comparisons. Mean daily exposure
was calculated in µg as the cumulative amount of ICS prescribed, divided
by number of days since ICS initiation; cumulative ICS exposure was
calculated in mg as the total dose prescribed over the follow-up period.
Mean daily and cumulative ICS exposures were expressed in ﬂuticasone
propionate–dose equivalents, as follows: doses of ﬂuticasone propionate,
ciclesonide, and extraﬁne-particle beclomethasone were reported as actual
doses and budesonide and ﬁne-particle beclomethasone dipropionate
doses were halved.50 Both mean daily ICS exposure and cumulative ICS
exposure were modeled as time-varying variables, meaning that at the
time of each new ICS prescription, the mean daily ICS dose and the
cumulative ICS dose up to that moment in time were updated.
We used the variables with at least 2% RCC (bias potential) for the ICS
group-only exposures for adjustment in the outcome models:
ICS mean daily exposure:
● For the diabetes onset cohort: none;
● For the diabetes progression cohort: number of acute OCS prescrip-
tions, glucose-regulating medication use;
● For the osteoporosis onset cohort: number of SAMA prescriptions.
ICS cumulative exposure:
● For the diabetes onset cohort: none;
● For the diabetes progression cohort: number of acute OCS prescrip-
tions, number of nasal corticosteroid prescriptions, number of SAMA
prescriptions;
● For the osteoporosis onset cohort: number of SAMA prescriptions.
In the ﬁnal matched data sets all variables with ≤ 10% missing values in
each treatment group and with RCC of at least 2% were identiﬁed for
adjustment in the outcome models. We expected that these variables
could have similar associations with exposure and/or outcome; therefore,
we assessed their conditional bias relative to the variables already in the
model. Starting with a model with exposure as the only explanatory
variable, we added additional variables one by one in order of their
individual bias potential, highest ﬁrst. After a variable was added to the
model it was retained if it caused a change-in-estimate of at least 2%
relative to the prior model.
Post hoc power calculations for the matched cohorts determined that
we had 80% power to show the following minimal HR for the ICS vs. LABD
comparisons:
● HR= 1.10 for diabetes onset,
● HR= 1.16 for diabetes progression, and
● HR= 1.11 for osteoporosis onset.
Analyses were conducted using Stata MP version 12 and Stata SE version
14 (StataCorp, College Station, TX). Statistically signiﬁcant results were
predeﬁned as P < 0.05.
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